Workflow
华北制药(600812) - 2024 Q4 - 年度业绩预告
600812NCPC(600812)2025-01-16 08:43

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 125 million yuan for 2024, an increase of about 120.11 million yuan compared to the same period last year, representing a year-on-year increase of approximately 2,456.08%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is around 107 million yuan, an increase of approximately 152.23 million yuan compared to the same period last year[3] - The total profit for the previous year was 158.54 million yuan, with a net profit attributable to shareholders of 4.89 million yuan[5] - The earnings per share for the previous year was 0.003 yuan[6] Profitability Factors - The company achieved profitability through product structure adjustments, improved procurement management, and cost control measures[7] - Non-recurring gains and losses for 2024 are expected to be around 18 million yuan, a decrease of approximately 32.12 million yuan compared to the previous year[7] Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant[8] - The company emphasizes that the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[9]